<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620135</url>
  </required_header>
  <id_info>
    <org_study_id>AR-13324-CS305</org_study_id>
    <nct_id>NCT04620135</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD&#xD;
      to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Open-Angle&#xD;
      Glaucoma or Ocular Hypertension Over A 4-Week Period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 9, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>This study adopts a single-masked study design. Therefore, to ensure masked state to the investigators and the clinical study team, the study medication bottles are placed in a sealed kit so that the study medication cannot be identified from the outside of the kit.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>29 Days</time_frame>
    <description>Mean diurnal IOP by treatment group by Goldmann applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP) at Weeks 1 and 2</measure>
    <time_frame>15 Days</time_frame>
    <description>Mean diurnal IOP at Weeks 1 and 2 (Days 8 and 15, respectively)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline IOP</measure>
    <time_frame>29 Days</time_frame>
    <description>Mean change from baseline in mean diurnal IOP at each post-treatment visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ripasudil hydrochloride hydrate ophthalmic solution 0.4%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop ripasudil twice dairy in the morning and evening in each eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil ophthalmic solution 0.02%</intervention_name>
    <description>Topical sterile ophthalmic solution Other Name: Rhopressa®</description>
    <arm_group_label>Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle</arm_group_label>
    <other_name>Netarsudil ophthalmic solution Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ripasudil hydrochloride hydrate ophthalmic solution 0.4%</intervention_name>
    <description>Other Name: Glanatec®</description>
    <arm_group_label>Ripasudil hydrochloride hydrate ophthalmic solution 0.4%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 years of age or older&#xD;
&#xD;
          -  Diagnosis of POAG or OHT in both eyes (POAG in one eye and OHT in the fellow eye is&#xD;
             acceptable)&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) +0.7 log MAR or better (20/100 Snellen or better&#xD;
             or 0.20 or better in decimal unit) in each eye&#xD;
&#xD;
          -  Willingness and ability to give signed informed consent and follow study instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant ocular disease&#xD;
&#xD;
          -  Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure&#xD;
             glaucoma, or narrow angles&#xD;
&#xD;
          -  Previous glaucoma intraocular surgery&#xD;
&#xD;
          -  Refractive surgery in either eye&#xD;
&#xD;
          -  Ocular trauma&#xD;
&#xD;
          -  Ocular infection&#xD;
&#xD;
          -  Any corneal disease&#xD;
&#xD;
          -  Known hypersensitivity to any component of netarsudil ophthalmic solution 0.02%,&#xD;
             ripasudil hydrochloride hydrate ophthalmic solution 0.4%, or to topical anesthetic.&#xD;
&#xD;
          -  Cannot demonstrate proper delivery of the eye drop&#xD;
&#xD;
          -  Clinically significant systemic disease&#xD;
&#xD;
          -  Participation in any investigational study within 30 days prior to screening&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or&#xD;
             not using a medically acceptable form of birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenji Aso, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals Ireland Ltd. (Japan Branch)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seijo Clinic</name>
      <address>
        <city>Setagaya-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma, Primary Open-Angle Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

